nerve blocking

W36017 is an impurity of lidocaine with a pKa of 7.4 for blocking neural activity.

Haloperidol is an effective dopamine D2 receptor antagonist that can be used to induce models of tardive dyskinesia and Parkinson’s disease.

Amifampridine (3,4-Diaminopyridine) is primarily used to treat rare muscle diseases. It blocks potassium channel efflux in nerve terminals, increasing action potential duration, which allows Ca2+ channels to remain open longer and enhances acetylcholine release to stimulate muscles at the end plate.

(+)-Sparteine ​​is a quinoline alkaloid extracted from Scotch broom, a sodium channel blocker and a class 1a antiarrhythmic agent. It competitively inhibits the activity of nicotinic acetylcholine receptors in nerve cells and is a ganglionic blocking agent.

Lycorenine may produce a decrease in blood pressure as the result of alpha-adrenergic blockade in conjunction with the reduction of the spontaneous sympathetic nerve activity, and produce bradycardia by modifying vagal activity. The development of tachyph

3- Deoxyaconitine is a derivative of Aconitine (A189875), which activates tetrodotoxin-sensitive Na+ channels, inducing presynaptic depolarization, thus blocking the nerve action potential which, in turn, blocks the release of neurotransmitters and decreases the end plate potential at the neuromuscular junction.

Ropivacaine mesylate, a long-acting amide local anaesthetic, is used for spinal block and effectively mitigates neuropathic pain. It achieves analgesia by reversibly inhibiting sodium ion influx in nerve fibers, thus blocking impulse conduction. Additionally, Ropivacaine acts as an inhibitor of the K2P (two-pore domain potassium channel) TREK-1, exhibiting an IC50 of 402.7 μM in COS-7 cell membranes.

Bupivacaine is a BK/SK, Kv1, Kv3, TASK-2 K Channel and voltage-gated Na channel blocker used as an anesthetic. It maybe neurotoxic at high does, inducing apoptosis in neuroblastoma cells. It acts by binding to the intracellular portion of voltage-gated sodium channels and blocking sodium influx into nerve cells.

TrkA-IN-3 is a selective small-molecule inhibitor with an IC₅₀ value of 22.4 nM. TrkA-IN-3 targets the tyrosine kinase activity of the nerve growth factor receptor TrkA, thereby blocking its downstream signaling pathways. In vitro, TrkA-IN-3 inhibits the proliferation and signal transduction of TrkA-positive cells and is commonly used to study the biological mechanisms underlying neuronal growth, pain signaling, and related tumor cells.

Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.

Pentapeptide-3, a pentapeptide fragment derived from waglerin-1 neurotoxin, is sourced from Temple Viper venom. This compound serves as a competitive antagonist of nicotinic acetylcholine receptors (nAChRs), blocking nerve signals at the post-synaptic membrane. Notably, Pentapeptide-3 exhibits anti-aging properties and is commonly incorporated with other cosmetic peptides for enhanced effects [1] [2].

GBR-900 is a humanized monoclonal antibody targeting Tropomyosin Receptor Kinase A (TrkA/NTRK1). TrkA is the high-affinity receptor for Nerve Growth Factor (NGF), widely expressed on sensory neurons of the dorsal root ganglia and basal forebrain cholinergic neurons in the central nervous system. The NGF/TrkA signaling pathway plays a pivotal role in pain transmission and the initiation and maintenance of chronic pain, particularly inflammatory and neuropathic pain. GBR-900 specifically binds to TrkA, blocking the interaction between NGF and its receptor, thereby inhibiting downstream pain signaling. Compared to antibodies directly targeting NGF, GBR-900 has demonstrated comparable analgesic efficacy in preclinical studies but with a superior safety profile (e.g., no dose-limiting toxicity). It is primarily investigated for the treatment of chronic pain, such as osteoarthritis pain.

Amifampridine-D3 dihydrochloride is a deuterated compound of Amifampridine dihydrochloride (T4497). Amifampridine 2hydrochloride has a CAS number of 54-96-6. Amifampridine is predominantly in the treatment of a number of rare muscle diseases. Amifampridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for a longer time and allow greater acetylcholine release to stimulate muscle at the end plate.